Product Description
FUJIFILM Toyama Chemical is developing Favipiravir (Avigan) as an influenza antiviral drug. Avigan selectively inhibits RNA polymerase necessary for influenza virus replication. Due to this mechanism of action, it is expected that Avigan may have an antiviral effect on the new coronavirus, as they are RNA viruses of the same type as influenza viruses. (Sourced from: https://www.fujifilmpharma.com/news/press-releases/anti-influenza-drug-avigan-tablet-meets-primary-endpoint-in-phase-iii-clinical-trial-in-japan-for-covid-19-patients)
Mechanisms of Action: RdRp Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Bangladesh | China | Egypt | Greece | Hungary | India | Indonesia | Japan | Jordan | Lebanon | Malaysia | Mexico | Peru | Romania | Russia | Slovenia | Turkey | Ukraine | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: FUJIFILM Toyama Chemical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France, Japan, Nigeria
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: COVID-19|Pneumonia
Phase 2: Lassa Fever
Phase 1: Communicable Diseases|Thrombocytopenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| FAVIDOSE | P1 |
Recruiting |
Communicable Diseases |
2027-06-01 |
|
| PROVIR | P3 |
Active, not recruiting |
COVID-19|Pneumonia |
2023-11-25 |
|
| jRCT2031220735 | P1 |
Active, not recruiting |
Thrombocytopenia |
2023-05-31 |
|
| SAFARI | P2 |
Completed |
Lassa Fever |
2022-11-10 |